Floatz logo

ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)

Bladder Adenocarcinoma

Emory Universityantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Bladder Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Ziv-Aflibercept
National Cancer Institute (NCI)
Phase 2B
Bms-907351
National Cancer Institute (NCI)
Phase 2CCC
Sorafenib
National Cancer Institute (NCI)
Phase 2CCC
Pembrolizumab
Emory University
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Atezolizumab
National Cancer Institute (NCI)
Phase 2CCC

Same molecule, other indications

ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) is also rated in:

urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urinary bladder neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
ureter neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →